Repare Therapeutics Inc. Comprehensive Income
Repare Therapeutics Inc. reported Comprehensive Income of $3.28 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2025-11-14
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was $3.28M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$16.76M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-03-31 was -$30.09M, a 331.07% decline year-over-year.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2024-12-31 was -$28.76M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$84.66M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$93.34M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$29.48M.
- Repare Therapeutics Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2021 was -$106.91M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-09-30 | $3.28M 10-Q · filed 2025-11-14 | -$13.48M derived: sum of 2 quarters · filed 2025-11-14 | -$43.57M 10-Q · filed 2025-11-14 | -$72.33M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | -$16.76M 10-Q · filed 2025-08-08 | -$46.85M 10-Q · filed 2025-08-08 | -$75.61M derived: sum of 3 quarters · filed 2025-08-08 | -$109.74M derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-03-31 | -$30.09M 10-Q · filed 2025-05-13 | -$58.84M derived: sum of 2 quarters · filed 2025-05-13 | -$92.98M derived: sum of 3 quarters · filed 2025-11-14 | -$127.77M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-12-31 | -$28.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$62.89M derived: sum of 2 quarters · filed 2025-11-14 | -$97.68M derived: sum of 3 quarters · filed 2025-11-14 | -$84.66M 10-K · filed 2025-03-03 |
| 2024-09-30 | -$34.13M 10-Q · filed 2025-11-14 | -$68.93M derived: sum of 2 quarters · filed 2025-11-14 | -$55.91M 10-Q · filed 2025-11-14 | -$83.66M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$34.80M 10-Q · filed 2025-08-08 | -$21.77M 10-Q · filed 2025-08-08 | -$49.52M derived: sum of 3 quarters · filed 2025-08-08 | -$68.23M derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | $13.02M 10-Q · filed 2025-05-13 | -$14.73M derived: sum of 2 quarters · filed 2025-05-13 | -$33.44M derived: sum of 3 quarters · filed 2025-05-13 | -$45.57M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$27.75M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$46.46M derived: sum of 2 quarters · filed 2025-03-03 | -$58.59M derived: sum of 3 quarters · filed 2025-03-03 | -$93.34M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$18.71M 10-Q · filed 2024-11-07 | -$30.84M derived: sum of 2 quarters · filed 2024-11-07 | -$65.59M 10-Q · filed 2024-11-07 | -$97.15M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$12.13M 10-Q · filed 2024-08-06 | -$46.88M 10-Q · filed 2024-08-06 | -$78.44M derived: sum of 3 quarters · filed 2024-08-06 | -$3.51M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$34.75M 10-Q · filed 2024-05-07 | -$66.31M derived: sum of 2 quarters · filed 2024-05-07 | $8.63M derived: sum of 3 quarters · filed 2024-05-07 | -$29.47M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$31.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $43.38M derived: sum of 2 quarters · filed 2024-02-28 | $5.28M derived: sum of 3 quarters · filed 2024-02-28 | -$29.48M 10-K · filed 2024-02-28 |
| 2022-09-30 | $74.94M 10-Q · filed 2023-11-09 | $36.84M derived: sum of 2 quarters · filed 2023-11-09 | $2.09M 10-Q · filed 2023-11-09 | -$26.20M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$38.09M 10-Q · filed 2023-08-09 | -$72.85M 10-Q · filed 2023-08-09 | -$101.14M derived: sum of 3 quarters · filed 2023-08-09 | -$132.03M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$34.76M 10-Q · filed 2023-05-09 | -$63.05M derived: sum of 2 quarters · filed 2023-05-09 | -$93.94M derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$28.29M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$59.18M derived: sum of 2 quarters · filed 2023-02-28 | -$106.91M 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$30.89M 10-Q · filed 2022-11-09 | -$78.62M 10-Q · filed 2022-11-09 |